Gilead makes another ADC move, inking up to $415M pact with Tubulisnews2024-12-03T12:00:44+00:00December 3rd, 2024|Endpoints News|
Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticalsnews2024-12-03T11:30:57+00:00December 3rd, 2024|Endpoints News|
J&J looks to expand Tremfya in two pediatric indicationsnews2024-12-02T18:34:00+00:00December 2nd, 2024|Endpoints News|
Biocon lands FDA approval for another Stelara biosimilarnews2024-12-02T18:11:06+00:00December 2nd, 2024|Endpoints News|
Novartis pays $1B upfront for PTC’s Phase 2 Huntington’s drugnews2024-12-02T12:35:53+00:00December 2nd, 2024|Endpoints News|
FDA is looking into hematology risks after patients take Bluebird’s Skysona gene therapynews2024-11-27T19:44:30+00:00November 27th, 2024|Endpoints News|
Novartis to cut 139 jobs in NJ as part of commercial refocusnews2024-11-27T16:54:45+00:00November 27th, 2024|Endpoints News|
Advanz Pharma faces revocation of European authorization for liver disease drug Ocalivanews2024-11-27T16:38:15+00:00November 27th, 2024|Endpoints News|
Bristol Myers sues the federal government over 340B, following other drugmakersnews2024-11-27T15:43:42+00:00November 27th, 2024|Endpoints News|
The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?news2024-11-26T21:09:00+00:00November 26th, 2024|Endpoints News|
